GLP-1 drugsReview

Diet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics

Advances in Clinical and Experimental Medicine

The paper

Adrian Kwaśny, Małgorzata Słoma-Krześlak, Grzegorz Kostelecki,

Anna Maria Rychter, Maria Brzegowy, Małgorzata Jeziorek, Matylda Kręgielska-Narożna, Ewa Lange, Iwona Boniecka, Aleksander Prejbisz, Piotr Dobrowolski,

Academy of Nutrition and Dietetics · Universidad de La Rioja

Advances in Clinical and Experimental Medicine · 2 Oct 2026

doi.org/10.17219/acem/235937 PubMed 42823936

GLP-1 agonists plus SGLT2 inhibitors lower kidney events in CKD
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
GLP-1 receptor agonists link to lower stroke and Alzheimer risk
Neurology Genetics · 4 Oct 2026